Crispr Therapeutics AG (CRSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.10B
Last updated: Nov 17, 2026 at 4:36 PM ET
Crispr Therapeutics AG (CRSP) Statistics
Crispr Therapeutics AG (CRSP) has a market cap of $4.10B and an enterprise value of $4.49B. It kept -1812.07% of revenue as net income over the last 12 months. Revenue fell 34.34% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 9.64% above the market cap, as debt exceeds cash.
| Market Cap | $4.10B |
|---|---|
| Enterprise Value | $4.49B |
| Latest price (Nov 17, 2026) | $40.15 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 154.3x and 2.4x. Its year-end P/S ranged from 6.3x to 426.9x from 2016 to 2024.
| P/S Ratio | 154.3x |
|---|---|
| Forward P/S | 115.5x |
| P/B Ratio | 2.4x |
Price Statistics
The stock is down 23.57% over 52 weeks and trades 22.02% below its 50-day average.
| Beta (1Y) | 1.86 |
|---|---|
| 52-Week Change | -23.57% |
| 1-Month Change | -19.76% |
| 3-Month Change | -32.87% |
| 6-Month Change | -15.63% |
| 5-Year Change | -43.70% |
| 10-Year Change | +181.75% |
| Total Return (1Y) | -23.57% |
| Total Return (3Y CAGR) | -16.06% |
| Total Return (5Y CAGR) | -13.52% |
| Return vs SPY (1Y) | -36.47% |
| Max Drawdown (1Y) | -35.13% |
| Max Drawdown (3Y) | -64.91% |
| Sharpe Ratio (1Y) | -0.50 |
| Correlation with SPY (1Y) | 0.44 |
| 50-Day Average | $51.49 |
| 200-Day Average | $52.42 |
| 52-Week Range | $39.83 to $63.45 |
| RSI (14 Days) | 28.9 |
| Average Volume (20 Days) | 1.78M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 16.21x current liabilities, and total debt is 0.36x shareholder equity.
| Current Ratio | 16.21x |
|---|---|
| Quick Ratio | 16.21x |
| Debt / Equity | 0.36x |
Returns and Efficiency
Return on invested capital is -20.30% over the last 12 months, against a 5-year average of -30.07%.
| Return on Equity (ROE) | -27.68% |
|---|---|
| Return on Assets (ROA) | -17.84% |
| Return on Invested Capital (ROIC) | -20.30% |
| Return on Capital Employed (ROCE) | -18.78% |
| ROE (5Y Average) | -15.26% |
| ROA (5Y Average) | -12.83% |
| ROIC (5Y Average) | -30.07% |
| Asset Turnover | 0.01x |
Scores
CRSP has an Altman Z-Score of 1.75, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.75 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $25.17M over the last 12 months.
| Revenue | $25.17M |
|---|---|
| Revenue Growth (YoY) | -34.34% |
| Gross Profit | $25.17M |
| Operating Income | -$532.33M |
| Pretax Income | -$453.65M |
| Net Income | -$456.13M |
| EBITDA | -$434.41M |
| EBIT | -$453.65M |
| Reported EPS (TTM) | -$4.74 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 64.45% of the $2.56B in total assets.
| Cash and Equivalents | $192.03M |
|---|---|
| Total Debt | $586.93M |
| Net Debt | $394.91M |
| Net Debt Per Share | $4.08 |
| Working Capital | $2.14B |
| Shareholder Equity | $1.65B |
| Book Value Per Share | $17.04 |
| Total Assets | $2.56B |
| Total Liabilities | $908.34M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.08M of capital spending, operating cash flow left -$376.71M of free cash flow.
| Operating Cash Flow | -$374.63M |
|---|---|
| Capital Expenditures | $2.08M |
| Free Cash Flow | -$376.71M |
| FCF Per Share | -$3.90 |
| Depreciation and Amortization | $19.23M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2114.75%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2114.75% |
| Pretax Margin | -1802.19% |
| Net Margin | -1812.07% |
| EBITDA Margin | -1725.78% |
| EBIT Margin | -1802.19% |
| FCF Margin | -1496.56% |
Growth
Revenue grew 43.09% a year over 3 years.
| Revenue Growth (3Y CAGR) | +43.09% |
|---|---|
| Revenue Growth (5Y CAGR) | +37.31% |
| Book Value Per Share Growth (2Y CAGR) | -3.92% |
| Tangible Book Per Share Growth (2Y CAGR) | -3.92% |
Dividends and Yields
CRSP does not pay a dividend. Its free cash flow yield is -9.70%.
| FCF Yield | -9.70% |
|---|---|
| Buyback Yield | -3.47% |
| Shareholder Yield | -3.47% |
Peer Position
Against 8 similar companies, CRSP has the highest P/S.
P/S RatioPeer median 7.2x
ROICPeer median -29.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -21.78%
| P/S Ratio | 154.3x vs 7.2x median |
|---|---|
| ROIC | -20.30% vs -29.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -34.34% vs -21.78% median |
Analyst Forecast
Consensus estimates put revenue growth at 518.04% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +518.04% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CRSP
What is CRSP's market cap?
Crispr Therapeutics AG has a market cap of $4.10B. Its enterprise value, which adds debt and subtracts cash, is $4.49B.
How many shares of CRSP are outstanding?
Crispr Therapeutics AG has 96.74M shares outstanding. The count is up 5.95% from a year earlier.
Does CRSP pay a dividend?
No. Crispr Therapeutics AG does not pay a dividend.
How much debt does CRSP have?
Crispr Therapeutics AG has $586.93M of total debt and $192.03M of cash and equivalents, a net debt position of $394.91M.
CRSP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors